Inherited TP53 Variants and Risk of Prostate Cancer
2021 · European Urology · 86 citations
https://doi.org/10.1016/j.eururo.2021.10.036
B
Bastien Nguyen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
119
Papers
3.2K
Citations
27
h-index
34
i10-index
Bastien Nguyen is an academic researcher. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer Genomics and Diagnostics & Pancreatic and Hepatic Oncology Research. The author has an h-index of 27, co-authored 102 publications.
ORCID: 0000-0002-6166-4746Papers by this author
worksClinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
2025 · Nature Medicine · 60 citations
https://doi.org/10.1038/s41591-024-03362-3
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
2024 · Journal of Clinical Oncology · 44 citations
https://doi.org/10.1200/jco-24-02086
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
2024 · Journal of Clinical Oncology · 31 citations
https://doi.org/10.1200/jco.23.02733
Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer
2019 · JNCI Journal of the National Cancer Institute · 23 citations
https://doi.org/10.1093/jnci/djz023
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
2024 · Clinical Cancer Research · 6 citations
https://doi.org/10.1158/1078-0432.ccr-24-2113
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat